Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: S-1

First Posted Date: 2006-01-19

Last Posted Date: 2014-02-25

Lead Sponsor: Asan Medical Center

Target Recruit Count: 96

Registration Number: NCT00278863

Locations: 🇰🇷
Seoul Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷
Kyung Pook National University Hospital, Daegu, Korea, Republic of

and more 6 locations

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Biological: cetuximab
Drug: capecitabine
Drug: docetaxel
Drug: Erlotinib
Drug: Gemcitabine
Drug: Irinotecan
Drug: mitomycin C
Drug: rapamycin
Procedure: conventional surgery

First Posted Date: 2006-01-13

Last Posted Date: 2018-10-24

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 249

Registration Number: NCT00276744

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Capecitabine in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: capecitabine

First Posted Date: 2006-01-11

Last Posted Date: 2020-01-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 26

Registration Number: NCT00274768

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
DeCesaris Cancer Institute at Anne Arundel Medical Center, Annapolis, Maryland, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.

Phase 2

Completed

Conditions: Breast Cancer
Neoplasm Metastasis

First Posted Date: 2005-12-28

Last Posted Date: 2011-02-25

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 130

Registration Number: NCT00270491

Locations: 🇫🇷
Hôpital HOTEL DIEU, Paris, France

Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

Phase 3

Terminated

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: capecitabine
Drug: oxaliplatin
Drug: floxuridine

First Posted Date: 2005-12-22

Last Posted Date: 2013-05-15

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 22

Registration Number: NCT00268463

Locations: 🇺🇸
Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸
CCOP - Christiana Care Health Services, Newark, Delaware, United States
🇺🇸
Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States

and more 28 locations